1 T-cell counts/percentages in 93 HIV-1-infected patients subdivided as follows: naive (n 5 63), elite controllers (n 5 19), long-term nonprogressors (n 5 7), and HIV-infected patients affected by tumor (n 5 4). The same analyses were performed in HIV-negative patients with cancer (n 5 53), hepatitis C virus-infected patients (n 5 17), and healthy donors (n 5 173). Results: HIV-infected patients had increased circulating levels of functional CD8 The pathogenesis of immunodeficiency during HIV infection is mainly related to the cytopathic effects exerted by the virus against infected CD4
1 T cells. 1, 2 However, this mechanism does not satisfactorily explain certain aspects of the disease. For instance, in the recent Strategic Timing of Antiretroviral Treatment study absolute CD4
1 T-cell counts were not predictive of AIDS and non-AIDS events (including non-AIDS tumors) because a number of these events were noted in both immediate versus delayed initiation of antiretroviral therapy (ART) at absolute CD4 counts of greater than 500 cells/mL. 3 Moreover, some HIV-infected patients might have reduced CD4
1 T-cell counts for several years without having immunodeficiency. 4 Conversely, HIV-infected patients with normal CD4
1 T-cell counts after ART initiation can present with severe opportunistic infections. 5, 6 Hence it is possible that other pathogenic mechanisms causing immunodeficiency might be at play during HIV infection. Regulatory T (Treg) lymphocytes mediate immune-suppressive functions contributing to immune homeostasis and regulation under physiologic conditions. 7, 8 Little is known about the role of these cells in HIV immunodeficiency pathogenesis. 9, 10 Both increased or reduced Treg cell activity could be deleterious for HIV-infected patients. An excessive immune-suppressive function would worsen the immunologic and clinical scenario. 11, 12 Conversely, impaired regulatory processes would lead to increased activation and proliferation of residual CD4 1 T lymphocytes, thus favoring viral infection and spread, and chronic inflammation. [13] [14] [15] To date, studies on alterations of CD4
1 Treg cells in HIV-infected patients led to controversial results, so that the precise role played by Treg cells in HIV pathogenesis is still unclear. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] In addition to CD4 T cells, the Treg cell compartment includes cells belonging to the CD8 1 T-cell lineage. 20 Among the various CD8
1 Treg cell subsets, a subgroup characterized by the CD8
1

CD28
2 CD127 lo CD39 1 phenotype has been found to be highly concentrated within the tumor microenvironment. There, these cells inhibit lymphocyte proliferative and cytotoxic functions, thus favoring tumor immune escape. [21] [22] [23] Interestingly, similarities in composition and function of Treg cell subsets between patients with tumors and those with HIV infection have been highlighted. 19 Here we analyzed CD8 1 CD28
Treg cells in HIV-infected patients, seeking to understand whether their frequency in the circulation might correlate with viral load and CD4 1 T-cell count and could be considered a biomarker of immunodeficiency and non-AIDS events.
METHODS Patients
This was an observational, longitudinal, multicenter study. Ninety-three HIV-1-positive patients (Table I) All parameters were collected in a relational database connected through a Web-based interface. 24, 25 The normalization of laboratory value ranges applied by the different units was achieved through the z score method, thus ensuring data harmonization. 26 Fifty-three HIV-negative patients with cancer were given a diagnosis and enrolled at the Internal Medicine and Clinical Immunology Unit and at the Urologic Unit of the University of Genoa-IRCCS Azienda Ospedaliero Universitaria San Martino-IST-Istituto Nazionale per la Ricerca sul Cancro of Genoa. Patients were affected by renal (n 5 21), bladder (n 5 23), prostate (n 5 2), skin (n 5 1), acute myeloid leukemia (n 5 1), thyroid (n 5 1), breast (n 5 1), myeloma (n 5 1), ovary (n 5 1), and bone (n 5 1) cancers. Seventeen pretreatment hepatitis C virus (HCV)-monoinfected patients were enrolled at the Infectious Diseases Unit of the University of Genoa-San Martino IRCCS Hospital.
One hundred seventy-three healthy donors were also enrolled at the Internal Medicine and Clinical Immunology Unit of the University of Genoa-San Martino IRCCS Hospital and at the Istituto di Ricerca Genetica e Biomedica (IRGB), CNR, Monserrato, as control subjects.
The study was carried out in compliance with the Helsinki Declaration and approved by the Ethical Committee of San Martino Hospital in Genoa (P.R.251REG2014). All enrolled patients provided written informed consent.
Measurement of plasma viral load in HIV-infected patients
Plasma viral load, measured in HIV RNA copies with a cutoff set at 40 copies/mL, was quantified by using the K-PCR-HIV1 (Siemens Health Care, Erlangen, Germany) and the Nucleosens HIV (bioMerieux, Marcy-l' Etoile, France) kits.
Purification of PBMCs and tumor lymphocyte infiltrates
PBMCs were purified from heparinized blood samples by means of centrifugation on Ficoll-Hypaque gradient (Biochrom AG, Berlin, Germany) for 30 minutes at 1800 rpm. Lymphocytes from surgical specimens were purified by filtering minced tissues with a sterile cell strainer (Falcon; BD Biosciences, San Jose, Calif) and running the collected cells on Ficoll gradient.
mAbs and immunofluorescence analyses
Immunofluorescence analyses were performed on 100 mL of fresh blood samples, incubating the cells with specific fluorochrome-conjugated mAbs at 48C for 30 minutes in the dark. Red cells were lysed with 2 mL of FACS Lysing Solution (BD Biosciences) and resuspended in 200 mL of the same solution. PerCP-Cy5.5-conjugated anti-HLA-DR, clone L243; and APC-conjugated anti-CD3, clone UCHT1 (BD Biosciences). Samples were analyzed by using a BD FACSCanto II flow cytometer (BD Biosciences) with BD FACSDiva software (version 6.0; BD Biosciences). Expression of the Ki-67 marker was analyzed, incubating 1 3 10 6 PBMCs with Aqua Dead (Molecular Probes, Thermo Fisher, Waltham, Mass) for 15 minutes at room temperature. Cells were washed with PBS-BSA 0.01% and incubated with the following mAbs for surface staining: BV510-conjugated anti-CD3, clone UCHT1 (BD Biosciences); APC-H7-conjugated anti-CD8, clone RPA-T8 (BD Biosciences); BV-605-conjugated anti-CD28, clone CD28.2 (BD Biosciences); PerCP-Cy5.5-conjugated anti-CD127, clone HIL-7R-M21 (BD Biosciences); and APC-conjugated anti-CD39, clone TU66 (BD Biosciences). After staining, the cells were fixed and permeabilized by using the Transcription Buffer Set (BD PharMingen) before intranuclear staining with FITC mouse anti-Ki-67 (BD Biosciences) for 30 minutes in the dark. The cells were washed with 1 mL of PBS-BSA 0.01% and resuspended in 300 mL of PBS. Samples were analyzed by using a BD Fortessa X20 flow cytometer (BD Biosciences) with the BD FACSDiva software (version 8.0; BD Biosciences).
Evaluation of HLA-A2-positive patients
Fifty microliters of fresh blood was incubated with 10 mL of unconjugated anti-HLA-A2 mAb, clone BB7.2, for 20 minutes at room temperature. 27 The cells were then washed and incubated with the FITC-conjugated goat anti-mouse IgG 1 secondary antibody (SouthernBiotech, Birmingham, Ala) Frequency of gag-specific CD8 1 T lymphocytes PBMCs (2 3 10 6 ) were incubated with A*02:01 HIV gag PE-conjugated 1-10 FLGKIWPSYK pentamers (TC Metrix, Epalinges, Switzerland) or PE-conjugated hTert ILAKFLHWL pentamers (ProImmune, Oxford, United Kingdom) as a negative control for 15 minutes at 48C. Cells were washed with PBS-BSA 0.01% and incubated with Live Dead/Aqua Dead (Molecular Probes, Thermo Fisher) for 15 minutes at room temperature. Cells were washed with PBS-BSA 0.01% and incubated with the following mAbs for surface staining: FITC-conjugated anti-CD8, clone RPA-T8 (BD Biosciences); PerCP-Cy5.5-conjugated anti-CD28, clone CD28.2 (BioLegend); APC-conjugated anti-CD39, clone TU66 (BD Biosciences); BV421-conjugated anti-CD127, clone HIL-7R-M21 (BD Biosciences); and APC-H7-conjugated anti-CD3, clone UCHT1 (BD Biosciences). After staining, the tubes were washed with 1 mL of PBS-BSA 0.01% and resuspended in 300 mL of BD FACS Lysing solution (BD Biosciences). The samples were analyzed by using a BD FACSCanto II flow cytometer (BD Biosciences) with BD FACSDiva software (version 6.0; BD Biosciences).
Sorting of CD8
1 CD28 2 CD127 lo CD39 1 Treg cells
T lymphocytes, purified from PBMCs by means of immunomagnetic bead separation with microbeads conjugated with mAb specific for the CD8 antigen (Dynal CD8 positive isolation kit; Invitrogen, Life Technologies, Paisley, United Kingdom), were labeled with FITC-conjugated anti-CD127, clone HIL-7R-M21 (BD Biosciences), PerCP-Cy5.5-conjugated anti-CD28, clone CD28.2 (BioLegend); PE-conjugated anti-CD39, clone TU66 (BD Biosciences); and BV421-conjugated anti-CD8, clone RPA-T8 (BD Biosciences). Cells were sorted by using the BD FACSAria (BD Biosciences) with BD FACSDiva software (version 6.0; BD Biosciences).
Proliferation suppression assay
The suppression activity of sorted CD8 (Fig 1, A) 
CD127
lo CD39 1 Treg cells was increased (mean, 4.8%) and was significantly (P < .001) greater than that observed in healthy control subjects (Fig 1, A) 23 Surprisingly, the frequency found in the circulation of HIV-infected patients was significantly (P < .001) higher than that present in the peripheral blood of 46 patients with cancer (mean, 1.7%) and was only lower than that observed within tumor infiltrates (in our hands the highest frequency thus far measured ; Fig 1, A) . 23 These results suggest that a massive expansion/recirculation of these cells occurs in HIV-infected patients, as further supported by absolute counts of circulating CD8 1 Treg cells is significantly (P < .001) lower than in HIV-infected patients (Fig 1, A) , strengthening the possibility that the preferential expansion of these cells in HIV-infected patients is specifically related to HIV itself and its peculiar interactions with the immune system. Moreover, in naive HIV-infected patients the frequency of CD8 
CD39
1 Treg cells in the circulation of healthy control subjects (Fig 1, B) . Moreover, when the CD4
1
CD25
hi CD127 lo and CD8
1 Treg cell subsets were considered together, they accounted for an increase in the circulation that was consistent in naive HIV-infected patients compared with healthy subjects (Fig 1,  C) (Fig 2, A) . However, stratifying the patients in relation to the current Centers for Disease Control and Prevention classification (stage A vs stages B and C), clear correlations were detected between CD8
1 Treg cell frequencies and either HIV viral load, absolute CD4
1 T-cell count, or percentage of CD4 1 T cells in stage A patients (Fig 2, B) but not in stage B or C patients (not shown). Importantly, when the analyses included values collected longitudinally at baseline and after 3, 6, 9, and 12 months from initiation of ART, highly significant correlations were observed in the whole cohort of patients (Fig 2, C, 
CD127
lo CD39 1 Treg cell frequency and viremia showed a tighter statistical association (r 5 .45) than those between either absolute T-cell counts (r 5 20.32) or CD4
1 T-cell percentages (r 5 20.30) with viremia (Fig 2, D) (Fig 3, A) . It is possible that the expanded pool of actively proliferating CD8
1
CD28
2 CD127 lo CD39 1 Treg cells in HIV-infected patients could represent a population of chronically stimulated CD8 1 T cells reacting against HIV itself. To test this, circulating HIV-specific CD8 1 T lymphocytes were identified by staining with HLA-A2 pentamers loaded with the HIV gag [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] peptide: phenotypic analysis revealed that a percentage of gag-reactive T lymphocytes ranging from 2% to 34% in 11 naive HLA-A2
1 HIV-infected patients had the CD8
1
CD28
2 CD127 lo CD39 1 phenotype (Fig 3, B, and Table II) . Interestingly, in all tested patients the percentage of gag-reactive CD8 respectively. Correlations were performed either considering only data collected before ART initiation (BASELINE; A and B) or data achieved at all the examined time points (ALL TIMEPOINTS, including baseline and 3, 6, 9, and 12 months after initiation of ART; C and D). Viremia is expressed as HIV RNA copies/mL on cube root transformation (c.r.). Fig 2, A, Correlations performed with data collected from all patients at baseline. Fig 2, B, Correlations performed with data collected only from stage A patients at baseline. Fig  2, C and D, Correlations performed with data collected from all patients at all time points (n 5 158; baseline and 3, 6, 9, and 12 months after initiation of ART). Correlations were calculated by using the Pearson correlation coefficient. Viremia is expressed as HIV RNA copies/mL and represented on a log 10 scale. 
immunosuppression of HIV-infected subjects. The precise molecular and cellular interactions leading to such a commitment, as well as the anatomic site at which it occurs, remain to be elucidated.
frequency is a possible biomarker of HIV infection
The fact that the correlations between the frequency of CD8
1 Treg cells and viral load, as well as CD4
1 T-cell counts or percentages, were only seen longitudinally in ART-treated patients but not at baseline of patients earmarked to commence ART leads to the hypothesis that CD8
1 Treg cell frequency itself could represent a new dynamic biomarker to monitor the course of the disease. To explore this possibility, we undertook a longitudinal analysis of the frequency of CD8 
CD28
2 CD127 lo CD39 1 Treg cell frequency was observed after the beginning of treatment (Fig 4) , a behavior reminiscent of programmed death 1 expression on T lymphocytes in HIV-infected patients. 29, 30 In parallel, a progressive significant reduction of viremia and an increase in both CD4 1 T-cell counts and percentages were observed (Fig 4) The reduction of circulating CD8
Treg cell frequencies remained significant (P 5 .03), even after adjustment for viremia and CD4
1 T-cell counts in the multivariable model. These findings suggest that during HIV infection, viremia gauges the expansion of T-cell subsets linked to regulatory function.
Arguably, CD8 1 CD28 2 CD127 lo CD39 1 Treg cell frequency can be used as a new biomarker for HIV infection and disease progression. To corroborate this idea, we determined the frequency of CD8
1 Treg cells in a cohort of untreated chronically HIV-infected patients divided into ECs (n 5 19; all with undetectable viral load, with a lower limit of detection <40 copies/mL) and LTNPs (n 5 7; viral load range, 136-7100 HIV RNA copies/mL). Interestingly, 14 (73.7%) of 19 ECs did not have CD8
1 Treg cells in their circulation. Moreover, the frequency of CD8
1
CD28
2 CD127 lo CD39 1 Treg cells in the EC group, but not in LTNP group, was significantly lower than that in naive HIV-infected patients (Fig 5) .
Interestingly, 6 (9.5%) of 63 naive HIV-infected patients did not show a decrease in CD8 1 CD28
2
CD127
lo CD39 1 Treg cell frequency after initiation of ART (see Table E1 in this article's Online Repository at www.jacionline.org). We focused on the clinical status of these patients. In particular, patients 20 and 27, who did not respond to ART therapy, had an increase in viral load after 6 months of ART; patients 2, 29, 32, and 33 had wasting syndrome (patient 33 also had an unresolved opportunistic infection, cryptococcosis) despite the decrease of viremia and the increase in absolute CD4
1 T-cell count. This suggests that an increase in CD8
1
CD28
2 CD127 lo CD39 1 Treg cell frequency might be a marker of virologic or clinical worsening independent of viremia and CD4
1 T-cell count. Accordingly, high circulating CD8
1
CD28
2
CD127
lo CD39 1 Treg cell frequencies (7.7%, 7.9%, and 2.2%, respectively) were found in 3 chronically HIV-infected patients at the time of tumor diagnosis (patients 69 and 72: skin and visceral disseminated Kaposi; patient 70: non-Hodgkin lymphoma) despite HIV RNA values of less than 100 copies/ mL. Another patient (patient 71) affected by lung cancer in remission after chemotherapy showed a rapid increase in CD8
1
CD28
2
CD127
lo CD39 1 Treg cell frequency (from 0% to 2.9%) at the time of diagnosis of brain metastasis. Altogether, these findings suggest that the CD8 1 CD28
Treg cell frequency might represent a new biomarker to assess ART lack of effect and/or identify those patients in whom the virologic response is not associated with a full clinical response because of concomitant opportunistic infections or tumors.
Treg cell frequency and immune activation HIV-related comorbidities in patients receiving ART with viremia control remain a clinical concern because they reduce life expectancy of HIV-infected patients compared with the general population. 31, 32 Comorbidities, such as central nervous system vasculopathy and atherosclerosis, cardiovascular disease, loss of bone mineral density, cognitive impairment, and HIV-related malignant diseases, are likely related to chronic activation of the immune system and to a condition of chronic inflammation that has been reported in HIV-infected patients. [33] [34] [35] [36] [37] [38] [39] Here the frequency of circulating CD8 HLA-DR 1 T lymphocytes (Fig 6) , suggesting that HIV infection sustains a chronic immune cell activation that is not strictly related to viremia levels but that is paralleled by progressive expansion of circulating CD8
1 Treg cells.
DISCUSSION
The results of this study show that (1) functional CD8
1 Treg cell counts are markedly increased in the circulation of HIV-infected patients, (2) monitoring their frequency in the peripheral blood of HIV-infected patients might represent a clinical biomarker, and (3) these CD8
1 Treg cells at least partially originate from an HIV-specific T-cell pool.
Thus far, the most studied Treg cell subtypes are those belonging to the CD4 1 T-cell compartment. 40 However, regulatory lymphocytes are also present within the CD8 1 T-lymphocyte subpopulation. Indeed, several CD8
1 Treg cell subsets have been described both in animals and human subjects. 20, 41 Similar to what occurs to CD4
1 Treg cells, some of these subsets generate within the thymus (natural CD8
1 Treg cells), whereas others develop at the periphery. 20, [41] [42] [43] Interestingly, high expression of CD28 antigen seems not to be compatible with commitment of 1 , which for the first time identifies invariably a specific CD8
1 Treg cell subpopulation. 23 These cells do not express forkhead box protein 3, CD25, and cytotoxic T lymphocyte-associated protein 4, distinguishing them from natural CD8
1 Treg cells. 23, 44 Moreover, they are negative for NKG2a, CD103, and CD122; are HLA class I restricted; and exert their suppressive activity through soluble factors, indicating a different nature from Qa1/HLA-E-restricted CD8 1 Treg cells. 22, 23, [45] [46] [47] [48] Interestingly, they express CD45RA but not CCR7 and hence can be considered terminally differentiated T cells. 22, 49 Analyzing different series of cancer specimens, we found these cells to be highly concentrated within the tumor microenvironment, where they can exert remarkable immunosuppressive activity because of their capacity to target both T-cell proliferation and cytotoxicity. [21] [22] [23] 50 Here, being aware of the pathogenic involvement of the CD39/ adenosine pathway in HIV infection, as well as the function of CD8
1 Treg cells, we investigated the presence of these cells in the circulation of HIV-infected patients and possible correlations between their frequency and established markers of disease activity. 51 Indeed, high levels of association were observed between CD8 
CD28
1 CD127 lo CD39 1 Treg cell frequency could also represent a biomarker of disease. Interestingly, these associations were seen in patients already undergoing ART but not at baseline in naive patients, with the exception of stage A patients. Importantly, CD8
1
CD28
1
CD127
lo CD39 1 Treg cell frequency was shown to be related not only to the markers of disease but also to the occurrence of comorbidity (for which they were early predictors). Hence it is conceivable that the statistical association with other markers of disease is interfered with by perturbing events (namely comorbidities), so that it can be detectable when the values of these markers are reset and harmonized by ART, a condition likely comparable with that of stage A asymptomatic patients.
The potential pathogenic and clinical relevance of CD8 
lo CD39 1 Treg cell expansion is the expression of a regulatory attempt of the immune system against T-cell activation and inflammation.
The finding of an inverted ratio between circulating CD4 1 T-cell and CD8 1 CD28
2
CD127
lo CD39 1 Treg cell suggests that both events might be pathogenically related in determining the immunodeficiency typical of HIV infection. In this regard an issue thus far unsolved was whether Treg cells are expanded or decreased in HIV-infected patients. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Our study provides the answer to this issue because we found that the associated frequency of circulating CD4 
CD28
2 CD127 lo CD39 1 Treg cell subsets is remarkably and consistently higher in HIV-infected patients than in healthy subjects. Hence these data indicate that expansion of the circulating Treg cell compartment represents a constitutive feature of HIV infection, corroborating the hypothesis that HIV-related immunodeficiency originates not only from the quantitative reduction in CD4 1 T-cell counts but also from a qualitative alteration of immune homeostasis because of an abnormal effector T/Treg cell ratio.
Interestingly, the pool of CD8 1 CD28 2 CD127 lo CD39 1 Treg cells in HIV-infected patients has been shown to contain cells reactive against HIV antigens. This finding, which is consistent with similar observations on CD4
1 Treg cells, leads to speculation that HIV-specific T cells are functionally committed to regulatory functions when they encounter the respective antigens. 52 This event might progressively spread tolerance to non-HIV antigens contributing to the onset of immunodeficiency, a phenomenon reminiscent of the process termed ''infectious tolerance.'' 53 The elucidation of HIV-driven mechanisms ''deviating'' HIV-reactive T cells toward a regulatory function might allow identification of the involved molecular pathways that could represent useful targets for new therapeutic agents. Indeed, the discovery of a stably expanded Treg cell compartment in patients with HIV infection associated with the previous knowledge relative to the increased T-lymphocyte expression of regulatory molecules, such as programmed death 1, might point to new therapeutic approaches based on Treg cell-targeting agents as checkpoint inhibitors. 29, 30 We thank Professors M. Zanetti and S. Kinloch for their helpful revision of data and precious suggestions. We thank Professor F. Cucca who supervised the Istituto di Ricerca Genetica e Biomedica cohort phenotyping. 
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